Navigation Links
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
Date:12/1/2008

-- Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss Phase 2 Study Results in AML --

SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced new data from its studies of voreloxin in acute myeloid leukemia (AML) will be presented during the 50th American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 5-9, 2008. Researchers will present updated interim data from the company's ongoing Phase 2 clinical trial of single-agent voreloxin (formerly SNS-595) for elderly patients with newly diagnosed AML and from its Phase 1b/2 study of voreloxin in combination with cytarabine for relapsed/refractory AML. In addition, results from the Phase 1 study of SNS-032, a selective inhibitor of cyclin dependent kinases 2, 7 and 9, in both chronic lymphocytic leukemia and multiple myeloma will be presented. Following are the details on each of these data presentations.

Sunday, December 7, 2008

Viewing: 9:00 a.m. to 8:00 p.m. PT

Presentation Time: 6:00 p.m. to 8:00 p.m. PT

Hall A, MosconeCenter

Abstract #1951

Title: "Phase 2 Study of Voreloxin (Formerly Known as SNS-595) as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Preliminary Safety and Clinical Responses (The REVEAL-1 Study)"

Poster Board II-45

Abstract #1955

Title: "Voreloxin (formerly known as SNS-595) in Combination with Cytarabine Demonstrates Preliminary Clinical Responses in a Phase 1 Study in Relapsed/Refractory Acute Myeloid Leukemia"

Pos
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
2. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
3. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
4. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
6. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
9. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
10. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
11. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... Chief Executive Officer of Neurocrine Biosciences, will be presenting at ... Conference in Boston.   The live presentation takes ... / 8:20 a.m. Pacific Time.  The presentation will be webcast ... http://www.neurocrine.com . If you are unable to ...
(Date:5/23/2013)... 23, 2013 Nephros, Inc. (OTC Bulletin Board: ... company that develops and sells high performance liquid purification ... offering.  In addition, the concurrent temporary reduction in exercise ... May 17, 2013. Nephros estimates that it ... rights offering.   A portion of the proceeds will be ...
(Date:5/23/2013)... May 23, 2013  A recently published clinical study ... Houston, Texas , demonstrates that 3D mammography (breast ... detection. The study, "Implementation of Breast ... was led by Stephen L. Rose ... the American Journal of Roentgenology (AJR). The ...
Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3
... POH, AIM: PSG, OTCQX: PPGNY) today announced that, ... Phase 1 transdermal,oxycodone clinical trial aimed at providing ... Phosphagenics has submitted all necessary documents for ... at CMAX - an independent clinical research,organization located ...
... First internal candidate to enter Phase 2 clinical ... PCOP ), an innovator in the discovery ... the initiation of a Phase 2a,clinical study of ... a dual-acting angiotensin and endothelin receptor antagonist,(DARA) that ...
Cached Medicine Technology:Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5
(Date:5/24/2013)... 24 (HealthDay News) -- New research suggests a ... people with insomnia. Every additional hour someone ... percent drop in the likelihood of moderate or ... the University of Pennsylvania. "We were ... sleep duration and suicide risk," study author, Linden ...
(Date:5/24/2013)... commonly used to treat glaucoma may cause droopy eyelids ... according to a new study. The drugs, known ... eye pressure, have already been shown to cause blurred ... said, suggesting that the new findings could lead to ... conservative when prescribing these drugs, the researchers added, particularly ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Area homeowners dreaming ... of new hot tubs to choose from at factory-direct pricing ... . The sales event takes place at Emerald Pool ... 2013. , Jacuzzi, the industry's leading hot tub brand, ... across the country. The event will feature popular hot tub ...
(Date:5/24/2013)... mutations central to the development of infantile myofibromatosis (IM)a ... and soft tissuemay provide new therapeutic targets, according to ... Sinai. The findings, published in the American Journal ... options for this debilitating disease, for which the only ... tumors. , IM is an inheritied disorder that develops ...
(Date:5/24/2013)... (HealthDay News) -- People with high levels of cadmium ... of liver disease than those with lower levels, a ... in urine is evidence of long-term exposure to the ... tobacco smoke, the Johns Hopkins researchers explained. They ... directly causes liver disease but instead suggest an association ...
Breaking Medicine News(10 mins):Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Truckload of Jacuzzi® Hot Tubs Rolls into Bend, Oregon on May 24, 2013 for Sales Event 2Health News:Researchers identify first drug targets in childhood genetic tumor disorder 2Health News:High Cadmium Levels May Raise Risk for Dying From Liver Disease: Study 2
... Jan. 13 Genomma Lab Internacional,S.A.B. de C.V. (BMV: ... the main preliminary indicators obtained at the close of ... slightly lower results than the,original growth expectations. However, product ... line with original projections. , ...
... welcomes Los Angeles Mayor Antonio Villaraigosa, Cal State ... representatives and other dignitaries for the construction dedication ... 13 Today, Grifols SA (Grifols), a global ... Los Angeles Mayor Antonio Villaraigosa., Cal State LA ...
... WASHINGTON, Jan. 13 Speaker Nancy Pelosi released ... bipartisan legislation to expand the State Children,s Health ... Similar bipartisan legislation was vetoed twice by President ... bill, click here http://www.speaker.gov/newsroom/legislation?id=0270: "Today, the House ...
... The following was released today by the Office of the ... , On Wednesday, ... Health Insurance Program (SCHIP) Reauthorization bill. This bipartisan bill ... 11 million children -- preserving coverage for the 7 ...
... SRA International, Inc. (NYSE: SRX ), ... and solutions to government organizations and commercial clients, will ... release after close of market on Thursday, Feb. 5, ... call beginning at 5 p.m. EST.Interested parties may listen ...
... helped with pain, fatigue and depression, study shows ... may help people living with the chronic pain ... quality of life, new research shows. , The ... Saarbrucken in Germany, found that fibromyalgia patients had ...
Cached Medicine News:Health News:Grifols Celebrates Initial Construction of New IVIG Facility with Los Angeles Officials and Dignitaries 2Health News:H.R. 2, Bipartisan Children's Health Bill, Will Provide Coverage to 11 Million Children 2Health News:H.R. 2, Bipartisan Children's Health Bill, Will Provide Coverage to 11 Million Children 3Health News:H.R. 2, Bipartisan Children's Health Bill, Will Provide Coverage to 11 Million Children 4Health News:SRA Schedules Second Quarter Fiscal Year 2009 Earnings Release and Conference Call 2
... Aegis CheckPoint is an automated, ... logging and alert system for refrigerator, ... replace chart recorders, data loggers and ... installs on an existing PC and ...
... as three tests confirmed Sterillium Rub's extremely ... to FDA (Time Kill study and Tentative ... Products) and one European test - with ... relevant international efficacy specifications. Sterillium Rub with ...
Chlorhexidine Gluconate, exceptionally persistent and broad spectrum antimicrobial properties have led to its recognition as the most effective agent available for surgical scrubbing, hand washing, p...
Amino+Derm moisturizers and soaps are specifically engineered to aid in the prevention of skin irritations and to help maintain healthy, intact skin....
Medicine Products: